![[1,2,4]triazyny – potencjalne leki w chemioterapii nowotworów Cover](/_next/image?url=https%3A%2F%2Fsciendo-parsed.s3.eu-central-1.amazonaws.com%2F647088b271e4585e08a9f607%2Fcover-image.png&w=384&q=75)
[1,2,4]triazyny – potencjalne leki w chemioterapii nowotworów
References
- Abi-Jaoudeh N.: TATE Versus TACE, an open-label randomized study comparing trans arterial tirapazamine embolization versus trans arterial chemo embolization in intermediate stage hepatocellular carcinoma. https://clinicaltrials.gov/ct2/show/NCT03145558 (12.12.2019)
- Ali R.S., Saad H.A.: Synthesis and pharmacological studies of unprecedented fused pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b] [1,3,4]thiadiazine derivatives. Molecules, 2018; 23: 1024
- Al-Temimay I.A., Al-Jibouri M.H., Hassan A.A., Mohammad F.I.: Test the cytotoxicity of pleurotin extracted from and edible mushroom Pleurotus osteratus against three human carcinoma cell line. Iraqi J. Sci., 2015; 56: 2773–2781
- Anjomshoa M., Fatemi S.J., Torkzadeh-Mahani M., Hadadzadeh H.: DNA- and BSA-binding studies and anticancer activity against human breast cancer cells (MCF-7) of the zinc(II) complex coordinated by 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine, Spectrochim. Acta A Mol. Biomol. Spectrosc., 2014; 127: 511–520
- Anjomshoa M., Hadadzadeh H., Fatemi S.J., Torkzadeh-Mahani M.: A mononuclear Ni(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: DNA- and BSA-binding and anticancer activity against human breast carcinoma cells. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2015; 136: 205–215
- Anjomshoa M., Hadadzadeh H., Torkzadeh-Mahani M., Fatemi S.J., Adeli-Sardou M., Rudbari H.A., Nardo V.M.: A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines. Eur. J. Med. Chem., 2015; 96: 66–82
- Arpino G., Wiechmann L., Osborne C.K., Schiff R.: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev., 2008; 29: 217–233
- Ashour H.M., El-Wakil M.H., Khalil M.A., Ismail K.A., Labouta I.M.: Synthesis of some (E)-6-[2-(furan-2-yl)ethenyl]-1,2,4-triazin-5-ones and their biological evaluation as antitumor agents. Med. Chem. Res., 2013; 22: 1909–1924
- Branowska D., Ławecka J., Sobiczewski M., Karczmarzyk Z., Wysocki W., Wolińska E., Olender E., Mirosław B., Perzyna A., Bielawska A., Bielawski K.: Synthesis of unsymmetrical disulfanes bearing 1,2,4-triazine scaffold and their in vitro screening towards anti-breast cancer activity. Monatsh Chem., 2018; 149: 1409–1420
- Bray F., Jemal A., Grey N., Ferlay J., Forman D.: Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol., 2012; 13: 790–801
- Cascioferro S., Parrino B., Spanò V., Carbone A., Montalbano A., Barraja P., Diana P., Cirrincione G.: Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives. Eur. J. Med. Chem., 2017; 142: 74–86
- Cortez D., Reuther G., Pendergast A.M.: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene, 1997; 15: 2333–2342
- Dinh Ngoc T., Moons N., Kim Y., De Borggraeve W., Mashentseva A., Andrei G., Snoeck R., Balzarini J., Dehaen W.: Synthesis of triterpenoid triazine derivatives from allobetulone and betulonic acid with biological activities. Bioorg. Med. Chem., 2014; 22: 3392–3300
- Dziadziuszko R., Zyśk R.: Rak płuca – korzyści kliniczne leczenia inhibitorami ALK w świetle ograniczeń ekonomicznych w Polsce. Onkol. Prakt. Klin. Edu., 2015; 1: 54–64
- El-All A.S., Hassan A.S., Osman S.A., Yosef H.A., Abdel-Hady W.H., El-Hashash M.A., Atta-Allah S.R., Ali M.M., El Rashedy A.A.: Synthesis, characterization and biological evaluation of new fused triazine derivatives based on 6-methyl-3-thioxo-1,2,4-triazin-5-one. Acta Pol. Pharm, 2016; 73: 79–92
- El-All A.S., Osman S.A., Roaiah H.M., Abdalla M.M., El Aty A.A., Abd El-Hady W.H.: Potent anticancer and antimicrobial activities of pyrazole, oxazole and pyridine derivatives containing 1,2,4-triazine moiety. Med. Chem. Res., 2015; 24: 4093–4104
- Ell-Wakil M.H., Ashour H.M., Saudi M.N., Hassan A.M., Labouta I.M.: Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity. Bioorg. Chem., 2018; 76: 154–165
- Elsayed E.H., Radwan E.M.: New potential antitumor nitrogen heterocycles: Synthesis and cytotoxic evaluation. Der Pharma Chemica, 2016; 8: 399–413
- Fink B.E., Norris D., Mastalerz H., Chen P., Goyal B., Zhao Y., Kim S.H., Vite G.D., Lee F.Y., Zhang H., Oppenheimer S., Tokarski J.S., Wong T.W., Gavai A.V.: Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg. Med. Chem. Lett., 2011; 21: 781–785
- Gao L.Z., Li T., Yu S.X., Huang W.L., Zhao H., Hu G.Q.: Design, synthesis, antibacterial and anti-cell proliferation activities of [1,2,4]triazino[3,4-h][1,8]naphthyridine-8-one-7-carboxylic acid derivatives. Acta Pharm. Sin., 2015; 50: 332–336
- Garajová I., Giovannetti E., Biasco G., Peters G.J.: c-Met as a target for personalized therapy. Transl. Oncogenomics, 2015; 7: 13–31
- Gavai A.V., Fink B.E., Fairfax D.J., Martin G.S., Rossiter L.M., Holst C.L., Kim S.H., Leavitt K.J., Mastalerz H., Han W.C., Norris D., Goyal B., Swaminathan S., Patel B., Mathur A. i wsp.: Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J. Med. Chem., 2009; 52: 6527–6530
- Gazieva G.A., Izmest’ev A.N., Anikina L.V., Pukhov S.A., Meshchaneva M.E., Khakimov D.V., Kolotyrkina N.G., Kravchenko A.N.: The influence of substituents on reactivity and cytotoxicity of imidazothiazolotriazinones. Mol. Divers., 2018; 22: 585–599
- Gucký T., Fryšová I., Slouka J., Hajdúch M., Džubák P.: Cyclo-condensation reaction of heterocyclic carbonyl compounds, Part XIII: Synthesis and cytotoxic activity of some 3,7-diaryl-5-(3,4,5-trimethoxyphenyl)pyrazolo[4,3-e][1,2,4]triazines. Eur. J. Med. Chem., 2009; 44: 891–900
- Gucký T., Řezníčková E., Džubák P., Hajdúch M., Kryštof V.: Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines. Monatsh Chem., 2010; 141: 709–714
- Gumulec J., Balvan J., Sztalmachova M., Raudenska M., Dvorakova V., Knopfova L., Polanska H., Hudcova K., Ruttkay-Nedecky B., Babula P., Adam V., Kizek R., Stiborova M., Masarik M.: Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int. J. Oncol., 2014; 44: 923–933
- Juszczyński P.: Nowe cele terapii ukierunkowanej w nowotworach układu chłonnego z perspektywy ostatnich 5 lat badań. Hematologia, 2015; 6: 1–9
- Karczmarzyk Z., Wysocki W., Urbańczyk-Lipowska Z., Kalicki P., Bielawska A., Bielawski K., Ławecka J.: Synthetic approaches for sulfur derivatives containing 1,2,4-triazine moiety: Their activity for in vitro screening towards two human cancer cell lines. Chem. Pharm. Bull., 2015; 63: 531–537
- Keane L.A.J., Mirallai S.I., Sweeney M., Carty M.P., Zissimou G.A., Berezin A.A., Koutentis P.A., Aldabbagh F.: Anti-cancer activity of phenyl and pyrid-2-yl 1,3-substituted benzo[1,2,4]triazin-7-ones and stable free radical precursors. Molecules, 2018; 23: 574
- Koziński K., Dobrzyń A.: Szlak sygnałowy Wnt i jego rola w regulacji metabolizmu komórki. Postępy Hig. Med. Dośw., 2013; 67: 1098–1108
- Krzeminski P.: Receptory nukleotydowe w komórkach nowotworowych. Postępy Biochemii, 2014; 60: 490–505
- Kwon Y.S., Nam J.H., Kim D.Y., Suh D.S., Kim J.H., Kim Y.M., Kim Y.T.: Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. J. Korean Med. Sci., 2009; 24: 679–683
- Lee C.I., Huang C.M., Huang W.H., Lee A.R.: Synthesis, preferentially hypoxic apoptosis and anti-angiogenic activity of 3-amino-1,2,4-benzotriazine-1,4-dioxide bearing alkyl linkers with a 3-amino-1,2,4-benzotriazine-1-oxide moiety. Anticancer Agents Med. Chem., 2014; 14: 1428–1446
- Li Q., Lescrinier E., Groaz E., Persoons L., Daelemans D., Herdewijn P., De Jonghe S.: Synthesis and biological evaluation of pyrrolo[2,1-f][1,2,4]triazine c-nucleosides with a ribose, 2′-deoxyribose, and 2′,3′-dideoxyribose sugar moiety. Chem. Med. Chem., 2018; 13: 97–104
- Lou J., Zhou X., Weng Q., Wang D.D., Xia Q., Hu Y., He Q., Yang B., Lou P.: XQ2, a novel TPZ derivative induced G2/M phase arrest and apoptosis under hypoxia in non-small cell lung cancer cells. Biosci. Biotechnol. Biochem., 2010; 74: 1181–1187
- Makki M.S.I., Abdel-Rahman R.M., Khan K.A.: Fluorine substituted 1,2,4-triazinones as potential anti-HIV-1 and CDK2 inhibitors. J. Chem., 2014; 2014: 430573
- Mojzych M.: Cytotoxic activity of some pyrazolo[4,3-e][1,2,4] triazines against human cancer cell lines. J. Chem. Soc. Pak., 2011; 33: 123–128
- Mojzych M., Bielawska A., Bielawski K., Ceruso M., Supuran C.T.: Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity. Bioorg. Med. Chem., 2014; 22: 2643–2647
- Mojzych M., Šubertová V., Bielawska A., Bielawski K., Bazgier V., Berka K., Gucký T., Fornal E., Kryštof V.: Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. Eur. J. Med. Chem., 2014; 78: 217–224
- Mojzych M., Tarasiuk P., Karczmarzyk Z., Juszczak M., Rzeski W., Fruziński A., Woźny A.: Synthesis, structure and antiproliferative activity of new pyrazolo[4,3-e]triazolo[4,5-b][1,2,4]triazine derivatives. Med Chem., 2018; 14: 53–59
- Nassar I.F.: Synthesis and antitumor activity of new substituted mercapto-1,2,4-triazine derivatives, their thioglycosides, and acyclic thioglycoside analogs. J. Heterocyclic Chem., 2013; 50: 129–134
- Ndagi U., Mhlongo N., Soliman M.E.: Metal complexes in cancer therapy – an update from drug design perspective. Drug Des. Devel. Ther., 2017; 11: 599–616
- Noriega-Guerra H., Freitas V.M.: Extracellular matrix influencing HGF/c-MET signaling pathway: Impact on cancer progression. Int. J. Mol. Sci., 2018; 19: 3300
- Ott G.R., Wells G.J., Thieu T.V., Quail M.R., Lisko J.G., Mesaros E.F., Gingrich D.E., Ghose A.K., Wan W., Lu L., Cheng M., Albom M.S., Angeles T.S., Huang Z., Aimone L.D., Ator M.A., Ruggeri B.A., Dorsey B.D.: 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J. Med. Chem., 2011; 54: 6328–6341
- Pastorekova S., Gillies R.J.: The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis and beyond. Cancer Metastasis Rev., 2019; 38: 65–77
- Powis G.: Triazine and hydrazine derivatives. W: Cancer Growth and Progression: H.E. Kaiser. Kluwer Academic Publishers, Dordrecht Netherlands, 1989, 113–118
- Ranjbar S., Edraki N., Khoshneviszadeh M., Foroumadi A., Miri R., Khoshneviszadeh M.: Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors. Res. Pharm. Sci., 2018; 13: 1–11
- Reddy S.B., Williamson S.K.: Tirapazamine: A novel agent targeting hypoxic tumor cells. Expert Opin. Investig. Drugs, 2009; 18: 77–87
- Saad H.A., Moustafa A.H.: Synthesis and anticancer activity of some new s-glycosyl and s-alkyl 1,2,4-triazinone derivatves. Molecules, 2011; 16: 5682–5700
- Saad H.A., Youssef M.M., Mosselhi M.A.: Microwave assisted synthesis of some new fused 1,2,4-triazines bearing thiophene moieties with expected pharmacological activity. Molecules, 2011; 16: 4937–4957
- Safaie Qamsari E., Safaei Ghaderi S., Zarei B., Dorostkar R., Bagheri S., Jadidi-Niaragh F., Somi M.H., Yousefi M.: The c-Met receptor: Implication for targeted therapies in colorectal cancer. Tumour Biol., 2017; 39: 1010428317699118
- Ścibor-Bentkowska D., Czeczot H.: Komórki nowotworowe a stres oksydacyjny. Postępy Hig. Med. Dośw., 2009; 63: 58–72
- Seibert W.: Uber den Mechanismus der Reaktion von Kishner-Wolff-Staudinger. I. Mildeilung. Chem. Ber., 1947; 80: 494–502
- Shang S., Hua F., Hu Z.W.: The regulation of β-catenin activity and function in cancer: Therapeutic opportunites. Oncotarget, 2017; 8: 33972–33989
- Shnider B.I., Frei E., Tuohy J.H., Gorman J., Freireich E.J., Brindley C.O.Jr., Clements J.: Clinical studies of 6-azauracil. Cancer Res., 1960; 20: 28–33
- Showalter H.D., Turbiak A.J., Fearon E.R., Bommer G.T.: Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same. Patent No. US 20110166144 A1, 2011
- Smith A.B., Thoma G., Van Eis M.: Monocyclic heteroarylcycloalkyldiamine derivatives. WO 2013171690 A1, 2013
- Soria J.C., Cortes J., Massard C., Armand J.P., De Andreis D., Ropert S., Lopez E., Catteau A., James J., Marier J.F., Beliveau M., Martell R.E., Baselga J.: Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann. Oncol., 2012; 23: 463–471
- Spoerri L., Oo Z.Y., Larsen J.E., Haass N.K., Gabrielli B., Pavey S.: Cell cycle checkpoint and DNA damage response defects as anticancer targets: From molecular mechanisms to therapeutic opportunities. W: Stress Response Pathways in Cancer: G. Wondrak, Springer, 2015; 29–49
- Stępień E., Jakubiak D.: Szlak Wnt jako potencjalny cel oddziaływania nanocząstek na komórki. W: Nanocząstki i nanomateriały, red.: J. Gromadzińska, W. Wąsowicz. Zarząd Główny Polskiego Towarzystwa Toksykologicznego, Łódź 2013, 194–204
- Sweeney M., Coyle R., Kavanagh P., Berezin A.A., Lo Re D., Zissimou G.A., Koutentis P.A., Carty M.P., Aldabbagh F.: Discovery of anti-cancer activity for benzo[1,2,4]triazin-7-ones: Very strong correlation to pleurotin and thioredoxin reductase inhibition. Bioorg. Med. Chem., 2016; 24: 3565–3570
- Sztanke K., Pasternak K., Sztanke M., Kandefer-Szerszeń M., Kozioł A.E., Dybała I.: Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones. Bioorg. Med. Chem. Lett., 2009; 19: 5095–5100
- Tadesse S., Caldon E.C., Tilley W., Wang S.: Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update. J. Med. Chem., 2019; 62: 4233–4251
- Voskoboynik O.Y., Kovalenko S.I., Shishkina S.V.: Benzo[e] [1,2,4]triazino[2,3-c][1,2,3]triazin-2-ones electro-deficient heterocyclic compounds with promising anticancer activity. Heterocycl. Commun., 2016; 22: 137–141
- Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R., Balimane P., Chang C., Chen C., Discenza L., Frennesson D., Gottardis M.M., Greer A., Hurlburt W., Johnson W. i wsp.: Discover of 2,4-disubstituted pyrrolo-[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J. Med. Chem., 2009; 52: 7360–7363
- Xin M., Zhang L., Tang F., Tu C., Wen J., Zhao X., Liu Z., Cheng L., Shen H.: Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4] triazine derivatives as novel hedgehog signaling pathway inhibitors. Bioorg. Med. Chem., 2014; 22: 1429–1440
- Yang S.J., Liu M.C., Zhao Q., Hu D.Y., Xue W., Yang S.: Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents. Eur. J. Med. Chem., 2015; 96: 58–65
- Yurttaş L., Demirayak Ş., Ilgın S., Atlı Ö.: In vitro antitumor activity evaluation of some 1,2,4-triazine derivatives bearing piperazine amide moiety against breast cancer cells. Bioorg. Med. Chem., 2014; 22: 6313–6323
- Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W.: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 1986; 12: 1239–1242
DOI: https://doi.org/10.5604/01.3001.0014.7145 | Journal eISSN: 1732-2693
Language: English
Page range: 64 - 84
Submitted on: Jan 8, 2020
Accepted on: Sep 11, 2020
Published on: Feb 4, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Anna Szymanowska, Agnieszka Gornowicz, Anna Bielawska, Krzysztof Bielawski, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.